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Abstract
A series of mutants with deletion in the extracellular portion of TrkB were expressed transiently and stably in mammalian
cells to examine the brain-derived neurotrophic factor (BDNF)-binding properties of TrkB. We found that these binding
activities were retained by the TrkB deletion mutant (TrkBv4) lacking most of the extracellular portion, cysteine-rich cluster
1 and 2, leucine-rich motif and most of the first immunoglobulin-like domain (Ig1). Furthermore, the results of the
neurotrophin selectivity, the equilibrium binding constant, auto-phosphorylation and BDNF dependent cell survival indicate
that TrkBv4 acts as a functional BDNF receptor comparable to wild-type TrkB. Thus, our findings showed that only the
carboxyl-terminal half of the extracellular portion of TrkB, which includes the Ig2 domain, is essential for the functional
BDNF receptor. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Neurotrophins display their biological activities
through activation of members of the Trk tyrosine
kinase receptor family [1^6]. The neurotrophic e¡ect
of BDNF is mediated by its speci¢c receptor TrkB
[7^12]. Binding of BDNF induces auto-phosphoryla-
tion of TrkB, which triggers the subsequent steps in
the signal transduction pathway. The extracellular
portion of TrkB, which is responsible for BDNF
binding, consists of two cysteine-rich clusters (Cys1
and Cys2), a leucine-rich motif (LRM) and two im-
munoglobulin-like domains (Ig1 and Ig2). Analyses
of the binding properties between BDNF and TrkB,
using the TrkA-TrkB chimera receptors expressed in
mammalian cells [13] and immunoadhesion mole-
cules including the extracellular portion of TrkA-
TrkB and TrkC-TrkB chimeras [14], revealed that
the Ig2 domain of TrkB confers both speci¢city
and a⁄nity to BDNF. However, TrkB variants
with LRM deletion demonstrated that LRM is cru-
cial for the BDNF-binding activity [15] and analyses
using maltose-binding protein-TrkB fusion protein
expressed in E. coli [16,17] showed that the fusion
protein with the Ig2 domain of TrkB did not have
any binding activities for BDNF. Another study
found two regions, LRM-Cys2 and a domain close
to the Ig2 domain, to be BDNF-binding domains in
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the soluble form of TrkB by a⁄nity separation and
chemical cross-linking [18]. These discrepancies may
be due to the di¡erent experimental conditions.
Under some conditions, the extracellular region of
TrkB might not preserve its native conformation.
In this report, we evaluated the domain important
for BDNF binding by using the membrane-inserted
TrkB mutants expressed in mammalian cells, where
TrkB mutants are expected to have the same native
conformation as wild-type TrkB.
2. Materials and methods
2.1. Wild-type TrkB and TrkB mutants expression
constructs
Mouse trkB cDNA was cloned in the mammalian
expression vector pEF-BOS [19], to yield a construct
for the expression of wild-type TrkB (pEF-BOS-
trkB). The trkB cDNA corresponding to the extra-
cellular portion of TrkB was subcloned in pBlue-
scriptII (Stratagene) and sequential deletions on the
cDNA sequence were introduced with a deletion mu-
tant kit (Takara). To express all mutants on cell sur-
faces, the cDNA sequence corresponding to the sig-
nal peptide was retained. After con¢rming the
appropriate deletions by nucleotide sequencing, the
deleted cDNA fragments of the extracellular domain
were replaced with pEF-BOS-trkB. The amino acid
residues deleted from the TrkB mutants were as fol-
lows: TrkBv1, v3^92; TrkBv2, v3^160; TrkBv3,
v3^194; TrkBv4, v3^218; TrkBv5, v3^262;
TrkBv6, v3^266.
2.2. Expression of wild-type TrkB and TrkB mutants
COS-1 and NIH-3T3 cells were cultured in Dul-
becco’s modi¢ed Eagle’s medium (Nikken) contain-
ing 10% fetal bovine serum (Intergen) at 37‡C in 5%
CO2. Wild-type TrkB and TrkB mutants were tran-
siently expressed in COS-1 cells by transfection of the
cDNA constructs using Lipofectamine (Gibco-BRL).
After 48 h of transfection, cells were washed with
PBS (Nissui) twice and harvested for further analy-
sis. For stable transformants of wild-type TrkB or
TrkBv4, each construct was co-transfected with
pSV2neo into NIH-3T3 cells. After 1 week of G418
treatment (300 Wg/ml), several colonies were picked
up by the cylinder cloning technique. The expression
of wild-type TrkB or TrkBv4 was con¢rmed by
Western analysis. The transformants with a high ex-
pression level of wild-type TrkB or TrkBv4 were
used for further experiments.
2.3. Binding assay
Binding assay using membrane fraction was car-
ried out as described [20]. The harvested cells were
washed with ice cold T10E1 (10 mM Tris HCl (pH
8.0)/1 mM EDTA). Cells were suspended with T10E1
and homogenized followed by centrifugation at
1000Ug for 5 min at 4‡C. The supernatant was cen-
trifuged again at 10 000Ug for 30 min at 4‡C. The
pellet (membrane fraction) was suspended with
T10E1 and protein concentration was measured.
The binding assay of wild-type TrkB and TrkB mu-
tants transiently expressed in COS-1 cells was carried
out using a scintillation proximity assay (SPA, Amer-
sham) system. Brie£y, the membrane fraction (equiv-
alent to a protein concentration of 5 Wg), pre-coupled
with 0.5 mg WGA-SPA-beads, was incubated with
100 pM of 125I-BDNF (NEN) in a 96-well microplate
in 100 Wl assay solution (20 mM HEPES bu¡er (pH
7.2), 300 mM KCl, 0.5%BSA). After 4 h of incuba-
tion at room temperature, the microplate was
counted with a micro-L counter (Wallac). The ¢lter
binding assay was performed for the stable trans-
formants of wild-type TrkB and TrkBv4. For com-
petition binding assay, the membrane fraction (5 Wg)
of cells was incubated for 2 h at 4‡C with 100 pM of
125I-BDNF with 5 pM to 300 nM unlabeled compet-
itor in the assay solution (20 mM HEPES bu¡er (pH
7.2), 150 mM KCl, 0.5% BSA). For saturation bind-
ing assay, the membrane fraction (5 Wg) of cells was
incubated for 2 h at 4‡C with 16^270 pM of 125I-
BDNF in the assay solution. Bound/free separation
was carried out using the hydrophilic Durapore
PVDF membrane ¢lter (Millipore, pore size 0.45
Wm). The ¢lter was washed three times with PBS
containing 0.1% BSA and 0.1% protamine sulfate.
Radioactivity on the ¢lter was measured with a Q-
counter (Aloka). Non-speci¢c binding was deter-
mined by incubating the membrane fraction in the
presence of 1000-fold excess unlabeled BDNF. The
speci¢c binding was calculated by subtracting the
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non-speci¢c binding from the total binding. All un-
labeled neurotrophins (BDNF, NGF and NT4) were
purchased from Peprotech.
2.4. Western analysis
Experiments were carried out at room temperature
except when otherwise mentioned. Protein in the
Laemmli sample bu¡er was subjected to SDS-
PAGE (MULTI GEL 7.5, Daiichi) and transferred
electrically onto a PVDF membrane. For the detec-
tion of wild-type TrkB and TrkB mutants, the PVDF
membrane was incubated with a blocking solution
(5% skim milk and 0.05% Tween 20 in PBS) over-
night at 4‡C, and then with an anti-Trk antibody (sc-
011, Santa Cruz) for 1 h. After washing with PBS/
0.05% Tween 20 for 30 min, the membrane was
blocked again for 15 min and incubated with HRP-
conjugated anti-rabbit IgG antiserum (KPL) for 1 h,
followed by washing for 1 h. The signal detection
was carried out using ECL system (Amersham).
The same method was used for phospho-tyrosine
(p-Tyr) detection except for the components of the
blocking solution (10 mM Tris-HCl (pH 8.0), 150
mM NaCl, 2% BSA and 0.05% Tween 20) and the
washing solution (10 mM Tris-HCl (pH 8.0), 150
mM NaCl and 0.05% Tween 20) and anti-p-Tyr anti-
body (Upstate Biotechnology) and HRP-conjugated
anti-mouse IgG antiserum (Cappel) for the ¢rst and
second antibodies.
2.5. Surface biotinylation
COS-1 cells, which transiently express wild-type
TrkB or TrkB mutants, were washed twice with
PBS and harvested with a cell lifter (Costar). The
cells were collected by centrifugation at 1000Ug for
5 min. The cells were suspended with PBS supple-
mented with 0.5 mg/ml sulfo-NHS-LC-S-S-biotin
(Pierce) and incubated on ice for 30 min. The cells
were washed once with ice-cold PBS and incubated
on ice with the cultured medium for 10 min, followed
by washing with ice-cold PBS. The washed cells were
suspended with a lysis bu¡er (PBS containing 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1%
Tween 80 and 10 Wg/ml PMSF) and incubated on
ice for 10 min. After removing insoluble material
by centrifugation at 10 000Ug for 10 min at 4‡C,
the lysate was incubated with streptavidin-conju-
gated beads (Dynabeads M-280, Dynal) with gentle
rotation for 30 min at 4‡C. The beads were recovered
by magnetic separation and washed twice with the
lysis bu¡er. The biotinylated protein recovered was
suspended in Laemmli sample bu¡er and boiled 10
min. After removal of the beads magnetically, the
sample was analyzed by Western blotting.
2.6. Auto-phosphorylation assay
NIH-3T3 cells stably expressing wild-type TrkB or
TrkBv4 were incubated with 100 ng/ml BDNF at
37‡C for 10 min. The cells were washed twice with
ice-cold PBS and harvested with RIPA bu¡er (PBS
containing 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, 10 Wg/ml PMSF and 1 mM orthovana-
date). After centrifugation at 1000Ug for 10 min at
4‡C, the cell lysate (supernatant) was incubated on
ice with the anti-Trk antibody for 1 h. Protein G-
sepharose was then added to the lysate, and incu-
bated again with gentle rotation at 4‡C for 1 h.
The immunoprecipitates were collected by centrifu-
gation, washed 4 times with RIPA bu¡er and sus-
pended in Laemmli sample bu¡er, followed by West-
ern analysis.
2.7. Survival assay
Survival assay of NIH-3T3 cells stably expressing
wild-type TrkB or TrkBv4 was carried out and
quanti¢ed as described previously [15]. Brie£y, cells
were plated 1000 cells/well in 96-well plates in the
cultured medium without serum supplemented with
12.5^200 ng/ml BDNF. After 60 h of incubation, the
viability of cells was measured by the MTT assay
[21].
3. Results
3.1. BDNF-binding abilities of transiently expressed
TrkB mutants
The extracellular portion of TrkB consists of two
cysteine-rich clusters (Cys1 and Cys2), a leucine-rich
motif (LRM) and two immunoglobulin-like domains
(Ig1 and Ig2) (Fig. 1). To determine the important
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region of TrkB for BDNF binding, several TrkB
mutants with sequential deletions from the amino-
terminal side (Fig. 1) were transiently expressed in
the COS-1 cells and their BDNF-binding abilities
were examined. The speci¢c binding of 125I-BDNF,
which was comparable to that of wild-type TrkB,
was observed in TrkBv2^v4 and a slightly weaker
BDNF binding was observed in TrkBv1 (Fig. 2A).
Whereas no signi¢cant BDNF binding was observed
in TrkBv5 or TrkBv6 (Fig. 2A). Since these results
may be due to ine⁄cient biosynthesis of some TrkB
mutants, we next examined the expression of TrkB
mutants. The membrane samples used for the bind-
ing assay were subjected to Western analysis using an
anti-Trk antibody that recognizes the intracellular
region of TrkB. As shown in Fig. 2B, each TrkB
mutant was expressed appropriately at the same level
as wild-type TrkB and also migrated in agreement
with each deletion. The broad signal observed was
most likely due to di¡erences in glycosylation be-
cause the extracellular portion of TrkB is known to
be heavily glycosylated [22]. We further examined
whether the TrkB mutants were expressed on the
cell surface. Cell surface biotinylation was performed
using sulfo-NHS-LC-S-S-biotin and the biotinylated
proteins were isolated from the cell lysates using
streptavidin-conjugated beads, followed by Western
analysis using anti-Trk antibody. The results shown
in Fig. 2C con¢rmed the appropriate presence of
each mutant on the cell surface as wild-type TrkB.
Therefore, removal of amino-terminal region from
TrkB mutants did not appear to interfere with bio-
synthesis and transport of TrkB mutants to the cell
surface.
We considered that the results of the speci¢c bind-
ing of 125I-BDNF (Fig. 2A) referred the BDNF-bind-
ing ability of each TrkB mutant. Transiently ex-
pressed TrkBv4, lacking most of the extracellularFig. 1. Schematic illustration of wild-type TrkB and its deletion
mutants. A series of constructs encoding deletion mutants of
the mouse TrkB were prepared as described in Section 2. Do-
mains of TrkB and their amino acid residues are according to
Schneider and Schweiger [25]; the cysteine-rich cluster 1 (Cys1,
residues 1^36), leucine-rich motif (LRM, residues 37^108), cys-
teine-rich cluster 2 (Cys2, residues 109^164), ¢rst and second
immunoglobulin-like domains (Ig1 and Ig2, residues 183^239
and 270^334, respectively) and transmembrane domain (TM,
residues 399^423). The intracellular portion including tyrosine
kinase domain is not shown in this illustration.
Fig. 2. BDNF-binding abilities of the transiently expressed
TrkB mutants. (A) Wild-type TrkB or TrkB mutants were tran-
siently expressed in COS-1 cells and the cell membrane frac-
tions were used for 125I-BDNF binding. The cell membrane
fraction prepared from vector-transfected COS-1 cells was used
as a negative control (CTL). The radioactivity of 125I-BDNF
(cpm) in each sample was measured in the absence (total bind-
ing, ¢lled bar) or presence (non-speci¢c binding, open bar) of
1000-fold excess unlabeled BDNF. The binding assay was per-
formed in duplicate and the means are shown. (B) Detection of
the TrkB mutants. The cell membrane fractions for the binding
assay were subjected to Western analysis using an anti-Trk anti-
body. Molecular weight marker (Bio-Rad) was used to estimate
the signal size. (C) Cell surface expression of trkB mutants. The
transfected cells were biotinylated using sulfo-NHS-LC-S-S-bio-
tin, an activated biotin for cell surface labeling. The biotiny-
lated protein was precipitated from the cell lysate by streptavi-
din-conjugated beads. The precipitates were analyzed by
Western blot using anti-Trk antibody.
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portion, had the BDNF-binding ability comparable
to wild-type TrkB.
3.2. Comparison of TrkBv4 with wild-type TrkB
To further investigate the properties of TrkB mu-
tants, the constructs for wild-type TrkB and TrkBv4
were stably transfected into the NIH-3T3 cell. We
prepared the cell membrane fractions from these sta-
ble transformants and examined the ligand selectivity
of TrkBv4. The competition binding assay was per-
formed using several unlabeled neurotrophins that
interact with the Trk family (Fig. 3A). There are
no signi¢cant di¡erences between TrkBv4 and wild-
type TrkB in ligand selectivity; both had a speci¢c
binding ability to BDNF and NT-4, but no binding
ability to NGF. We further examined the equilibrium
binding constant (Kd) of the interaction of 125I-
BDNF with wild-type TrkB and TrkBv4 by satura-
tion binding assay. The binding properties with in-
creased 125I-BDNF showed that both wild-type TrkB
and TrkBv4 had 125I-BDNF binding with saturation
(Fig. 3B). The Kd value analyzed by the Scatchard
plot from three independent experiments were
84 þ 42 pM for wild-type TrkB, which was in the
same range previously reported [11,23]. Surprisingly,
TrkBv4 showed a Kd value of 91 þ 10 pM, which was
quite similar to that of wild-type TrkB. The BDNF-
induced auto-phosphorylation assay was also carried
out to examine whether TrkBv4 is activated to in-
duce signaling by BDNF. After exposure to BDNF
for 10 min, the stable transformants expressing wild-
type TrkB and TrkBv4 were harvested. The lysed
cells were immunoprecipitated by the anti-Trk anti-
body, and the precipitates were subjected to Western
analysis using anti-phosphotyrosine antibody. Both
wild-type TrkB and TrkBv4 were signi¢cantly auto-
phosporylated by BDNF stimulation (Fig. 3C). Fi-
Fig. 3. TrkBv4 acts as a functional BDNF receptor comparable
to wild-type TrkB. (A) Comparison of the neurotrophin selec-
tivity. NIH-3T3 cell membrane stably expressing wild-type
TrkB or TrkBv4 was used for competition binding assay. The
radioactivity of 125I-BDNF (cpm) was measured in the presence
of the various concentration of unlabeled competitor, BDNF
(closed circle), NGF (open triangle) and NT-4 (open square).
The binding assay was performed in duplicate and means are
shown. (B) Saturation binding assay of wild-type TrkB and
TrkBv4. Representative results are shown. The membrane frac-
tion prepared from NIH-3T3 cells stably expressing wild-type
TrkB or TrkBv4 were incubated with various concentrations of
125I-BDNF and speci¢c binding was determined as described in
Section 2. Experiments were performed in duplicate and the
means of speci¢c binding for wild-type TrkB (open squares)
and TrkBv4 (closed circles) were plotted on the graph. Similar
results were obtained in three independent experiments. (C)
BDNF-induced auto-phosphorylation assay. NIH-3T3 cells sta-
bly expressing wild-type TrkB or TrkBv4 were incubated in the
absence (3) or presence (+) of 100 ng/ml BDNF for 10 min.
The cells were lysed and subjected to the immunoprecipitation
using the anti-Trk antibody. The immuno-precipitates were ana-
lyzed by Western blotting using an anti-phosphotyrosine anti-
body (upper panel) or the anti-Trk antibody (lower panel). Mo-
lecular weight marker (Bio-Rad) was used to estimate the signal
size. (D) Survival assay. NIH-3T3 cells stably expressing wild-
type TrkB or TrkBv4 were cultured in serum-free medium sup-
plemented various concentration of BDNF. The viability with-
out BDNF was determined as 1. The viability was measured by
MTT assay. The survival assay was performed in triplicate and
means and standard deviations are shown.
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nally, the BDNF-dependent cell survival assay was
carried out. The transformants expressing wild-type
TrkB and TrkBv4 were cultured in serum-free me-
dium supplemented various concentration of BDNF,
and the viability of cells was examined by the MTT
assay. Consistent with the binding assay and auto-
phosphorylation assay, the BDNF dependent surviv-
al of TrkBv4 was the same level as wild-type TrkB
(Fig. 3D).
The results of the ligand selectivity, the equilib-
rium binding constant, auto-phosphorylation and
BDNF-dependent cell survival indicate that
TrkBv4, which lacks Cys1 and Cys2, LRM and
most of Ig1 in the extracellular portion, acts as a
functional BDNF receptor comparable to wild-type
TrkB.
4. Discussion
The importance of the Ig2 domain of TrkB for
BDNF binding has been reported by several groups
[13,14,18]. This importance was also con¢rmed with
other Trk receptors, TrkA and TrkC [14,24]. These
results agree with our ¢ndings that TrkB mutants,
TrkBv1^v4, possessed signi¢cant BDNF-binding ac-
tivities, besides we could not detect any BDNF bind-
ing in TrkBv5 or TrkBv6 both of which contain the
whole Ig2 domain. The absence of the BDNF-bind-
ing activity was also observed using the cell mem-
brane sample stably expressing TrkBv5 (data not
shown). Our results suggest that not only the Ig2
domain, but also the internal region between Ig1
and Ig2 plays an important role in BDNF binding.
Deletion of the internal region between Ig1 and Ig2
might destroy the native conformation of the Ig2
domain.
In transient expression in COS-1 cells, wild-type
TrkB was found to migrate with an estimated molec-
ular weight (MW) of 120 kDa (Fig. 2B), which was
slightly lower than the native TrkB of 145 kDa [8].
This observation was most likely due to the transi-
ently expressed TrkB being less glycosylated. In spite
of partial glycosylation, transiently expressed wild-
type TrkB and TrkB mutants in COS-1 cells do
not a¡ect the BDNF-binding activities (Fig. 2A).
However, as partial glycosylation of TrkB may a¡ect
some BDNF-induced biological activities, stable
transformants expressing wild-type TrkB and
TrkBv4 were prepared for further experiments. The
estimated MW of stably expressed wild-type TrkB
and TrkBv4 were approximately 145 and 96 kDa,
respectively, which were larger than those transiently
expressed. This result suggests that stably expressed
wild-type TrkB and TrkBv4 are su⁄ciently glycosyl-
ated.
We found BDNF-binding, BDNF-induced auto-
phosphorylation properties and BDNF-dependent
survival using stable transformants of wild-type
TrkB or TrkBv4. We showed that TrkBv4 acts as
a functional BDNF receptor and the amino-terminal
region of the extracellular portion including Cys1,
LRM, Cys2 and Ig1 domains was not essential.
But this result did not agree with the reports that
LRM of TrkB plays an important role in BDNF
binding [15^17]. Ninkina et al. reported no BDNF-
binding activity of TrkB variants lacking only LRM
expressed in NIH-3T3 which was the same as our
expression system [15]. Interestingly, we also ob-
tained that TrkBv1 which lacks Cys1 and most of
LRM had a slightly weaker BDNF-binding ability
than wild-type TrkB and TrkBv2^v4 (Fig. 2A).
From these observations, it seems that lacking of
LRM, Cys2 interferes with the binding of BDNF.
Further study of the precise structure of TrkB should
clarify role of LRM and Cys1 and Cys2.
Our results clearly demonstrated that TrkBv4
lacking the amino-terminal region of the extracellular
portion including Cys1, LRM, Cys2 and Ig1 do-
mains acts as a functional BDNF receptor compara-
ble to wild-type TrkB.
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